A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
Completed · Phase 3 · NCT03781167
Conditions: Parkinson's Disease (PD)
At a glance
- Research payments reported, 2025
- $8,105
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 244
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-951 (drug)
- Dates
- Started 2019-04-29; completion 2022-08-17
- Results posted
- Yes
The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.
From ClinicalTrials.gov, last updated 2023-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $8,105 in research payments for this study in 2025 (1 payments).
Products named: Vyalev
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Kumc Research Institute Inc $8,105
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.